News

FDA appoints biotech veteran George Tidmarsh to lead drug evaluation division
Stanford's George Tidmarsh has authored 143 scientific papers and patents, as well as played a central role in developing ...
STAT5d
New head of FDA drug center is a biotech veteran and an outspoken critic of the academic establishment
“Dr. Tidmarsh is an accomplished physician-scientist and leader whose experience spans the full arc of drug development — ...
FDA appoints biotech executive as top drug regulator under RFK Jr.
Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...
PharmExec3d
FDA Appoints George Tidmarsh as Director of Center for Drug Evaluation and Research
Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...
FDA Picks George Tidmarsh to Head Center for Drug Evaluation and Research
By Stephanie Brown HealthDay ReporterWEDNESDAY, July 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has appointed George Francis Tidmarsh, M.D., Ph.D., as director of the Center ...
Former biotech executive appointed to lead FDA drug office
George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...
FDA names former pharmaceutical company executive to oversee US drug program
The Food and Drug Administration on Monday named a longtime pharmaceutical executive to run the agency’s drug program, the ...
Biotech exec George Tidmarsh picked as FDA's chief drug regulator
The U.S. Food and Drug Administration named ex-biotech exec George Tidmarsh as its chief drug regulator. FDA Commissioner ...
FDA to appoint George Tidmarsh as top drug regulator, Bloomberg News reports
U.S. Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the ...
FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths
The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a ...
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and ...